Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $1.01M rose 181.2% year over year, behind the +311.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 95.6% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.
Context
- Financing cash flow amounted to 56.0% of revenue in FY2025, up 27.4 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +181.2% toward the trailing-twelve-month pace of +311.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 25.01M USD
- Year-over-year change
- +283.7%
- 4-year CAGR
- +49.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.01M | +283.7% |
| FY2024 | 2024-12-31 | (13.62M) | -305.1% |
| FY2023 | 2023-12-31 | 6.64M | -68.0% |
| FY2022 | 2022-12-31 | 20.73M | +316.5% |
| FY2021 | 2021-12-31 | 4.98M | — |
Financing Cash Flow vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +311.3% is the 2nd highest of 8, against a peer median of +23.9%.
- Financing cash flow amounts to 50.1% of revenue for FRX.TO, versus a peer median of 22.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$399.12M CAD | +168.5% | — | 128.4% | |
| LTM Mar 2026 | $122.16M USD | +399.3% | +78.9% | — | |
| LTM Mar 2026 | $67.77M USD | -43.9% | +11.5% | 22.2% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $42.16M USD | +23.9% | +81.2% | 224.7% |
| LTM Mar 2026 | $25.62M USD | +311.3% | +6.4% | 50.1% | |
| LTM Apr 2026 | CA$5.32M CAD | +36.5% | -23.3% | — | |
| LTM Mar 2026 | CA$2.03M CAD | -101.9% | — | 0.7% | |
| LTM Mar 2026 | $601.11K USD | -96.6% | +4.6% | 0.2% | |
| Peer median (excluding FRX.TO) | — | +23.9% | +11.5% | 22.2% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Depreciation & Amortization | 0 | 0 | 0 | 800K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.02M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (932K) | 1.1M | (6.78M) | 16.94M | (12.04M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.44M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.28M) |
| Accounts Payables | (794K) | 1.61M | 1.39M | (537K) | 1.39M |
| Other Working Capital | (138K) | 1.61M | 683K | 24.77M | 282K |
| Other Non-Cash Items | 307K | 466K | 326K | 4.61M | (26.45K) |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 19.94M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22K) | 797K | 1.64M | (439K) | (190.27K) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 25.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.5M) |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 8.83M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.